Estradiol cypionate is 17% estradiol β- Cyclopentyl propionate can inhibit the synthesis of ET-1 through estrogen receptor. It is a long-acting estrogen drug.

2-(Diethylamino)Ethyl 2-(Naphthalen-1-Ylmethyl)-3-(Oxolan-2-Yl)Propanoate

MSDS

CAS:31329-57-4

Molecular Formula:C24H33NO3

Alias

More Information

Ls 84; Praxilene; 2-Diethylaminoethyl 1-(Tetrahydro-2-Furyl)-3-(1-Naphthyl)Propane-2-Carboxylate; 3-<Naphthyl-1->-2-<Tetrahydrofuranyl-2-Methyl>-Propionsaeure-<3-Diethylamino-Ethylester>; 2-(Diethylamino)Ethyl 3-(Naphthalen-1-Yl)-2-((Tetrahydrofuran-2-Yl)Methyl)Propanoate; Dusodril; Naftidrofuryl; Naftidrofuryl [Inn:Ban]; Naphtidrofuryl; Tridus; Naftidrofurylum [Inn-Latin]; 2-<Tetrahydro-Furfuryl>-3-<1-Naphthyl>2-Diaethylamino-Aethylester>Nafronyl; Nafronyl

Brief Introduction

Peripheral vasodilators.

Regadenoson

MSDS

CAS:313348-27-5

Molecular Formula:C15H18N8O5

Alias

More Information

Lexiscan; Rapiscan; Unii-7Axv542Lz4

Brief Introduction

Regardson monohydrate is the hydrate of regardson. Regardson is a new A2A adenosine receptor agonist developed by CVTherapeutics. It was approved by FDA for myocardial perfusion imaging in April 2008.

N-(2-Chloro-4-Methylthiophen-3-Yl)-4,5-Dihydro-1H-Imidazol-2-Amine

MSDS

CAS:31428-61-2

Molecular Formula:C8H10ClN3S

Alias

More Information

Tiamenidinum; Tiamenidine; Hoe-42-440; Hoe-440; Tiamenidina; Symcor Base Tts; Unii-195V08O55G

Brief Introduction

The chemical structure of central antihypertensive drugs is similar to clonidine. By stimulating central postsynaptic α 2-adrenergic receptors, thereby reducing peripheral sympathetic tone. For the treatment of essential hypertension.

Centchroman

MSDS

CAS:31477-60-8

Molecular Formula:C30H35NO3

Alias

More Information

Ormeloxifene; Centaurein; Unii-V994Wjy688; V994Wjy688; 1-[2-[4-[(3S,4S)-7-Methoxy-2,2-Dimethyl-3-Phenyl-3,4-Dihydrochromen-4-Yl]Phenoxy]Ethyl]Pyrrolidine

Brief Introduction

Levormeloxifene is an experimental selective estrogen receptor modulator that was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss. The development was stopped because of a high incidence of gynaecologic adverse events during clinical trials. It is the enantiomer of ormeloxifene.

Inquiry (

/ 10

)

Clear All